research Novel investigational drugs for alopecia areata and future perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
Search
for
Sort by
Research
660-690 / 1000+ results research Winer's dilated pore, rare presentation in the external ear canal
Accurate diagnosis of Winer's dilated pore in the ear is crucial to avoid unnecessary aggressive treatment.
research Cardiodermatology: the heart of the connection between the skin and cardiovascular disease
research Acupuncture for treating alopecia areata: A systematic review and meta-analysis
Acupuncture may help with hair regrowth in alopecia areata, but more research is needed.
research Alopecia Areata: The Clinical Situation
Treating alopecia areata is difficult due to limited approved treatments, but new therapies like JAK inhibitors show promise.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: A Real‐World Cohort Study
Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
research The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review
Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.
research Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
AA patients with comorbid conditions face more severe hair loss and need specific treatments.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research A CASE STUDY ON AYURVEDIC MANAGEMENT OF ALOPACIA AREATA- THROUGH EXTERNAL TREATMENT
Ayurvedic treatment led to significant hair regrowth in alopecia areata.
research Effect of Orostachys iwarenge Hara on the proliferation of dermal papilla ceIls
Orostachys iwarenge Hara extract may help promote hair growth.
research Study on the regulatory effect of Ligusticum chuanxiong on inflammation of human dermal papilla cells in alopecia areata based on network pharmacology and in vitro experiment
research Pitfalls of overzealous iconodiagnosis of the Girl with a Pearl Earring
Vermeer likely omitted eyebrows for style, not due to hair loss.
research MODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW
JAK inhibitors show promise for treating alopecia areata, but more research is needed.
research Role of the Autoimmune Regulator (AIRE) gene in alopecia areata: Strong association of a potentially functional AIRE polymorphism with alopecia universalis
A specific gene change is linked to severe hair loss.
research Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
New medications could improve treatment for severe alopecia areata in Australia.
research Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
research Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.
research Baricitinib (Olumiant)
Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
research The fate of non-scalp hair in alopecia areata universalis under baricitinib treatment: A real-world single-center experience
Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.
research Alopecic and Aseptic Nodules of the Scalp/Pseudocyst of the Scalp: Clinicopathological and Therapeutic Analyses in 11 Korean Patients
The research provided insights into the presentation and management of alopecic and aseptic nodules of the scalp.
research Adjunctive Dupilumab Therapy in a Partial Responder to Baricitinib for Alopecia Areata
Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research Efficacy of baricitinib in treatment of coexisting alopecia areata and lichen planopilaris
Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.
research Multiple, hereditary dome-shaped papules and acrochordons. Birt-Hogg-Dube syndrome
The boy likely has a fungal infection causing hair loss.
research A Clinical Trial on Efficacy of Gagamchengyoung-tang(Jiājiǎnqīngyíng-tāng) in the Alopecia Patients with Febrile Tendency
Gagamchengyoung-tang may help improve hair growth and scalp health in certain alopecia patients.
research AN AYURVEDIC APPROACH IN THE MANAGEMENT OF ALOPECIA AREATA (INDRALUPTA): A CLINICAL CASE REPORT
Ayurvedic treatment successfully managed Alopecia Areata.
research A CLINICO-INVESTIGATIVE STUDY OF ALOPECIA AREATA WITH SPECIAL REFERENCE TO ITS ASSOCIATION WITH VARIOUS SYSTEMIC AND DERMATOLOGICAL DISORDERS
Alopecia Areata is often linked to other health issues like allergies, thyroid problems, and diabetes.